Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$554.39 USD

554.39
120,830

+5.12 (0.93%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $554.63 +0.24 (0.04%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters

The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters

    John Blank headshot

    The World Cup Begins: Global Week Ahead

    We have lots of global events this week, counted in terms of soccer games, a historic diplomatic summit, and three major monetary policy meetings.

      Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates

      Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.

        LHCG or CHE: Which Is the Better Value Stock Right Now?

        LHCG vs. CHE: Which Stock Is the Better Value Option?

          Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?

          Style Box ETF report for VIOG

            Why Is Chemed (CHE) Up 13.6% Since Its Last Earnings Report?

            Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Amedisys or Chemed: Which is a Better Investment Choice?

              After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

                Chemed (CHE) Stock is Worth a Bet Right Now: Here's Why

                Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.

                  BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat

                  BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.

                    STERIS (STE) Q4 Earnings & Revenues Beat Estimates, Up Y/Y

                    Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.

                      Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact

                      We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.

                        Align Technology (ALGN) Beats on Earnings and Revenues in Q1

                        Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.

                          Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View

                          Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.

                            Chemed (CHE) Hits a 52-Week High, Can the Run Continue?

                            Chemed Corporation is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for CHE for clues.

                              CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow

                              CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.

                                Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q4

                                Abaxis (ABAX) Q4 earnings gain on strength in Medical and Veterinary segments.

                                  ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth

                                  ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.

                                    Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1

                                    Omnicell's (OMCL) first-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.

                                      GNC Holdings (GNC) Beats on Q1 Earnings, Plans Store Shutdown

                                      GNC Holdings (GNC) announces plans to shutter roughly 200 stores in 2018 as part of the ongoing optimization of the company's store portfolio in Q1.

                                        Stryker (SYK) Q1 Earnings Beat Estimates, 2018 View Solid

                                        Stryker (SYK) gains from strong segmental show in Q1; a solid guidance is promising.

                                          Varian Medical (VAR) Beats Q2 Earnings & Revenue Estimates

                                          Strong performance in the Software, Hardware and Service revenues boost Varian Medical's (VAR) Q2 results.

                                            CONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 Guidance

                                            CONMED (CNMD) gains on strong performance in core segments; raised guidance buoys optimism.

                                              Baxter (BAX) Beats on Q1 Earnings & Revenues, Raises '18 View

                                              Solid performance in Renal Products, Medication Delivery, Pharmaceutical and Other segment boost Baxter's (BAX) Q1 results.

                                                Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop

                                                Zimmer Biomet (ZBH) issues full-year 2018 sales and earnings guidance in Q1.

                                                  Align Technology (ALGN) Beats on Earnings and Revenues in Q1

                                                  Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.